<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46093">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506179</url>
  </required_header>
  <id_info>
    <org_study_id>P15-325</org_study_id>
    <nct_id>NCT02506179</nct_id>
  </id_info>
  <brief_title>Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis</brief_title>
  <acronym>UCanADA</acronym>
  <official_title>A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the real-life effect of adalimumab on psychological distress/depression symptoms
      in moderate-to-severe Ulcerative Colitis (UC) patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Psychological Distress assessed using Patient Health Questionnaire 9 Questions (PHQ-9)</measure>
    <time_frame>From Week 0 to Week 52 or at the time of Premature Discontinuation</time_frame>
    <description>This instrument self-administered version of the depression scale from the PRIME-MD (Primary Care Evaluation of Mental Disorders) instrument and is used to assess the level of depression severity (for initial treatment decisions) as well as an outcome tool (to determine treatment response). The PHQ-9 contains 9 items, each of which is scored 0 to 3, providing a 0 to 27 severity score. Cutpoints of 5, 10, and 15 represent mild, moderate, and severe levels of depressive symptoms, respectively. The final question on the PHQ-9 allow obtaining the patient's global impression of symptom-related impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Health Related-QOL (Quality of Life)</measure>
    <time_frame>From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Validated instruments filled both by the patient and the treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Endpoints Simple Clinical Colitis Activity Index (SCCAI)</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Used to access response and remission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in productivity</measure>
    <time_frame>From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Validated instruments filled both by the patient and the treating physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functionality</measure>
    <time_frame>From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Validated instruments filled both by the patient and the treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mayo endoscopic sub-score</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation.</time_frame>
    <description>Used to access response and remission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab parameters: C-reactive protein (CRP) milligram/ liter (mg/L)</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Used to access response and remission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab parameters: Hemoglobin (Hb) gram/ liter (g/L)</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Used to access response and remission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab parameters: Albumin (Ab) gram/ liter (g/L)</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Used to access response and remission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab parameters: White Blood Count (WBC) 10^9/Liter</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Used to access response and remission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab parameters: Platelets 10^9/Liter</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Used to access response and remission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab parameters: Calprotectin microgram/ gram (µg/g)</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Used to access response and remission rates</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Open-label cohort</arm_group_label>
    <description>Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult males and females with moderate to severe UC patients from Canada who meet the
        inclusion criteria and who do not meet any of the exclusion criteria will be eligible for
        enrollment into the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must voluntarily sign and date a patient authorization.

          -  Patient must be ≥ 18 years of age.

          -  Patient must have confirmed diagnosis of UC.

          -  Patient must have: a) moderate to severe UC (a Mayo endoscopic sub score of 2 or 3)
             from endoscopic investigation in the previous 3-months that is closest to the
             baseline visit or b) a Mayo rectal bleeding subscore ≥ 2 and a calprotectine value
             greater than 250 µg/gr.

          -  Patient must have been previously treated with conventional therapy including
             corticosteroids, azathioprine and/or 6-mercaptopurine (6-MP), and who have had an
             inadequate response to or who are intolerant to such therapies.

          -  Patient must have been prescribed adalimumab as part of his treatment by his treating
             physician.

        Exclusion Criteria:

          -  Patient has previously received adalimumab or another anti- tumor necrosis factor
             alpha (TNFα) or biologic therapy, including but not limited to Remicade (infliximab),
             Simponi (golimumab), Tysabri (natalizumab), Entyvio (vedolizumab).

          -  Patient with a history of subtotal colectomy with ileorectostomy or colectomy with
             ileoanal pouch, Kock pouch, or ileostomy for UC or planned bowel surgery.

          -  Patient with a current diagnosis of indeterminate colitis, ulcerative proctitis only,
             or with a current diagnosis and/or have a history of Crohn's disease.

          -  Patient with other tumor necrosis factor (TNF) immune-modulated disease.

          -  Patient has a significant history of renal, neurologic, psychiatric, endocrinologic,
             metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the
             investigator would adversely affect his/her participating in this study.

          -  A female patient is pregnant or breast-feeding.

          -  Patient is currently participating in another prospective study including controlled
             clinical trials and observational studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Pelizon, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Elharrar</last_name>
    <phone>514-832-7470</phone>
    <email>patrick.elharrar@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Lemay</last_name>
    <phone>514-832-7494</phone>
    <email>suzanne.lemay@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scope Clinic /ID# 144241</name>
      <address>
        <city>Brampton</city>
        <zip>L6S 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary Health Sciences Center /ID# 144032</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIUSS Saguenay Lac St-Jean /ID# 144801</name>
      <address>
        <city>Chicoutimi</city>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GI Research /ID# 141109</name>
      <address>
        <city>Edmonton</city>
        <zip>T5H 4B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta /ID# 141105</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute, University of Alberta /ID# 145973</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital /ID# 139398</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dr. Everett Chalmers Regional Hospital /ID# 136534</name>
      <address>
        <city>Fredericton</city>
        <zip>E3B 5N5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare /ID# 148011</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences /ID# 136825</name>
      <address>
        <city>Hamilton</city>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel-Dieu de Levis /ID# 137099</name>
      <address>
        <city>Levis</city>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre /ID# 144033</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Maisonneuve-Rosemont /ID# 137336</name>
      <address>
        <city>Montreal</city>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Saint-Luc /ID# 139393</name>
      <address>
        <city>Montreal</city>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital-MUHC /ID# 136821</name>
      <address>
        <city>Montreal</city>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Medical L'Enjeu /ID# 153690</name>
      <address>
        <city>Montreal</city>
        <zip>H3P 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oshawa Clinic /ID# 144364</name>
      <address>
        <city>Oshawa</city>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital /ID# 139392</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUL, Lipid Research Center /ID# 147557</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du CHUQ - CRCEO /ID# 137395</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital, Saskatoon, SK, Canada /ID# 137838</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier universitaire de Sherbrooke (CHUS) /ID# 137840</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr Chadwick Ian Williams Professional Corporation /ID# 144802</name>
      <address>
        <city>St. John</city>
        <zip>E2K 1J5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kensington Screening Clinic /ID# 141106</name>
      <address>
        <city>Toronto</city>
        <zip>M53 TA9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital-Toronto /ID# 141108</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Gordon and Leslie Diamond Centre /ID# 141523</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GIRI Gastrointestinal Research Institute /ID# 141107</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z-2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Services, Ltd. /ID# 144102</name>
      <address>
        <city>Victoria</city>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Percuro Clinical Research, Ltd. /ID# 136533</name>
      <address>
        <city>Victoria</city>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Kenneth Atkinson, Westminster, Canada /ID# 136820</name>
      <address>
        <city>Westminster</city>
        <zip>V3L 3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr O Tarabain Clininc /ID# 144034</name>
      <address>
        <city>Windsor</city>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Rahman Bacchus Medicine Corporation /ID# 141780</name>
      <address>
        <city>Windsor</city>
        <zip>N8Y 4C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>June 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe ulcerative colitis (UC)</keyword>
  <keyword>Real-life effect</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Ulcerative colitis (UC)</keyword>
  <keyword>Patient reported outcomes (PRO)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
